

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-34. (Canceled)

35. (Previously presented) A method for accelerating neovascularization of a wound, comprising applying to the wound an angiogenically effective amount of a pharmaceutical composition comprising an isolated polypeptide comprising the amino acid sequence of

(a) the mature human AL-2 amino acid sequence shown in Figure 1A-1C (SEQ ID NO: 2) or Figure 2A-2D (SEQ ID NO: 4); or

(b) a soluble AL-2 derived from SEQ ID NO: 2 or SEQ ID NO: 4; or

(c) a mammalian homolog or a conservative amino acid substitution variant of (a) having at least 95% sequence identity with SEQ ID NO: 2 or SEQ ID NO: 4,

and a physiologically acceptable carrier.

36-39. (Canceled)

40. (Currently amended) The method of claim 39 ~~35~~ wherein said wound is due to surgical incision, burn, traumatized tissue, skin graft, or ulcer.

41. (Previously presented) The method of claim 35 wherein normal healing of said wound is retarded.

42. (Previously presented) The method of claim 41 wherein the retardation is due to advanced age, diabetes, cancer, or treatment with an anti-inflammatory drug or an anticoagulant.

43. (Previously presented) The method of claim 35 wherein said composition is a topical composition.

44. (Previously presented) The method of claim 43 wherein said topical composition is in the form of an irrigant or salve.

45. (Previously presented) The method of claim 35 wherein said composition is contained in a suture, graft, or dressing.
46. (Previously presented) The method of claim 35 wherein said composition is a sustained release composition.
47. (Previously presented) The method of claim 35 wherein a clustered soluble AL-2 of the formula (soluble AL-2)<sub>n</sub> is applied to the wound, wherein n is 2 or greater.
48. (Previously presented) The method of claim 35 wherein an immunoadhesin comprising a soluble AL-2 is applied to the wound.
49. (Previously presented) The method of claim 35 wherein a compound of the formula (AL-2)<sub>n</sub>X is applied to the wound, wherein AL-2 is any of the polypeptides defined in parts (a)-(c) of claim 35, and n is 2 or greater, and X is an organic linker covalently binding each AL-2.